SCHEMBL10246707

SCHEMBL10246707

CCCCCCCCCCCCCCCC(=O)NCCCCC(=O)NC(CCS(C)(=O)=O)C(N)=O

nearest known ligand 0.54

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ NOD1 Q9Y239 4/20 0.54
▸ TLR2 O60603 1/20 0.50
▸ CASP2 P42575 1/20 0.48
▸ FAAH O00519 3/20 0.47
▸ LPAR3 Q9UBY5 4/20 0.46
▸ SLC6A5 Q9Y345 2/20 0.46
▸ LPAR1 Q92633 2/20 0.46
▸ NAAA Q02083 1/20 0.46
▸ DNM1 Q05193 1/20 0.45
▸ EPHX2 P34913 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10246700 0.92 NOD1 (0.52) NOD1TLR2FAAHSLC6A5DNM1
SCHEMBL15084766 0.88 NOD1 (0.63) NOD1TLR2CASP2FAAHLPAR3
SCHEMBL28960755 0.87 NOD1 (0.61) NOD1TLR2CASP2FAAHDNM1
SCHEMBL28960756 0.87 NOD1 (0.61) NOD1TLR2CASP2FAAHDNM1
SCHEMBL10246462 0.86 LPAR3 (0.54) NOD1TLR2LPAR3LPAR1
SCHEMBL22386556 0.84 NAAA (0.61) NOD1TLR2CASP2FAAHNAAA
SCHEMBL22726965 0.81 SLC6A5 (0.46) NOD1TLR2FAAHSLC6A5DNM1
SCHEMBL10248399 0.81 TLR2 (0.62) NOD1TLR2SLC6A5DNM1
SCHEMBL20471131 0.81 ALB (0.61) NOD1TLR2CASP2FAAHSLC6A5
SCHEMBL608666 0.80 FAAH (0.54) NOD1FAAHLPAR3SLC6A5DNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3744729-B1 PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMOPHARMACEUTICAL USES SEDERMA SA (FR) 2023-03-01 — — EP disclosed
EP-3744729-A1 COMPOUNDS, IN PARTICULAR PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMOPHARMACEUTICAL USES SEDERMA (FR) 2020-12-02 — — EP disclosed
EP-2382230-B1 PEPTIDES KXK, COMPOSITIONS LES COMPRENANT ET UTILISATIONS COSMETIQUES ET DERMO-PHARMACEUTIQUES. SEDERMA SA (FR) 2018-05-23 — — EP disclosed
US-8697656-B2 Compounds, in particular peptides, compositions comprising them and cosmetic and dermo-pharmaceutical uses SEDERMA (FR) 2014-04-15 — — US disclosed
US-8697656-B2 Compounds, in particular peptides, compositions comprising them and cosmetic and dermo-pharmaceutical uses SEDERMA (FR) 2014-04-15 — — US disclosed
US-20120014887-A1 NEW COMPOUNDS, IN PARTICULAR PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMO-PHARMACEUTICAL USES SEDERMA (FR) 2012-01-19 — — US disclosed
US-20120014887-A1 NEW COMPOUNDS, IN PARTICULAR PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMO-PHARMACEUTICAL USES SEDERMA (FR) 2012-01-19 — — US disclosed
WO-2010082177-A2 NEW COMPOUNDS, IN PARTICULAR PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMOPHARMACEUTICAL USES SEDERMA (FR) 2010-07-22 — — WO disclosed
WO-2010082175-A2 NEW COMPOUNDS, IN PARTICULAR PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMOPHARMACEUTICAL USES SEDERMA (FR) 2010-07-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120014887-A1 NEW COMPOUNDS, IN PARTICULAR PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMO-PHARMACEUTICAL USES CUTA, PLOD3, MC1R NOD1 4096/4885TLR2 1036/4885CASP2 2641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback